Is entresto part of the pde5 family?

Is Entresto a PDE5 inhibitor?

No. Entresto (sacubitril/valsartan) is not part of the PDE5 family and it is not a PDE5 inhibitor.

Entresto is a combination of:
- Sacubitril: a neprilysin inhibitor (it increases levels of natriuretic peptides)
- Valsartan: an angiotensin II receptor blocker (ARB)

PDE5 inhibitors (such as sildenafil and tadalafil) work by inhibiting phosphodiesterase type 5, which increases cGMP signaling—used mainly for erectile dysfunction and pulmonary arterial hypertension.

What category is Entresto in instead?

Entresto is prescribed for heart failure and works through the neprilysin/NP pathway and RAAS blockade via an ARB, not through PDE5/cGMP modulation.

Could patients confuse it with PDE5 drugs?

Sometimes. Both heart-related conditions and shared patient discussions can lead to confusion, but mechanistically Entresto and PDE5 inhibitors target different pathways.

Where to check drug mechanisms and classification

For drug-specific background and market history, DrugPatentWatch.com can help when you’re comparing products and their therapeutic classes: https://www.drugpatentwatch.com/